Clinicopathological implications of the expression of hypoxia-related proteins in gastric cancer

International Journal of Medical Sciences

Volumn 10, Issue 9, 2013, Pages 1217-1223

  Jung, Ji Han ^a   Im, Soyoung ^a   Jung, Eun Sun ^b   Kang, Chang Suk ^c  

^a The Catholic University of Korea   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c The Catholic University of Korea   (South Korea)

Author keywords

CA 9; Gastric cancer; GLUT 1; HIF 1 ; Hypoxia; iNOS

Indexed keywords

CARBONATE DEHYDRATASE IX; GLUCOSE TRANSPORTER 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INDUCIBLE NITRIC OXIDE SYNTHASE;

ADULT; ADVANCED CANCER; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXIA; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PROTEIN EXPRESSION; SOLID TUMOR; STOMACH ADENOCARCINOMA; SURVIVAL PREDICTION; TUMOR INVASION; UNIVARIATE ANALYSIS;

EID: 84881271697     PISSN: 14491907     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijms.6054     Document Type: Article

References (25)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61: 69-90.
2. Kim JG, Chung HY, Yu W. Recent advances in chemotherapy for advanced gastric cancer. World J Gastrointest Oncol. 2010; 2: 287-94.
3. Brahimi-Horn MC, Chiche J, Pouyssegur J. Hypoxia and cancer. J Mol Med (Berl). 2007; 85: 1301-7.
4. Griffiths EA, Pritchard SA, Welch IM, Price PM, West CM. Is the hypoxia-inducible factor pathway important in gastric cancer? Eur J Cancer. 2005; 41: 2792-805.
5. Maxwell PH, Pugh CW, Ratcliffe PJ. Activation of the HIF pathway in cancer. Curr Opin Genet Dev. 2001; 11: 293-9.
6. Eckert AW, Kappler M, Schubert J, Taubert H. Correlation of expression of hypoxia-related proteins with prognosis in oral squamous cell carcinoma patients. Oral Maxillofac Surg. 2012; 16: 189-96.
7. Kim JA, Kim SJ, Do IG, et al. Hypoxia-associated protein expression in primary central nervous system diffuse large B-cell lymphoma: does it predict prognosis? Leuk Lymphoma. 2011; 52: 205-13.
8. Kwon HC, Kim SH, Oh SY, et al. Clinicopathological significance of p53, hypoxia-inducible factor 1alpha, and vascular endothelial growth factor expression in colorectal cancer. Anticancer Res. 2010; 30: 4163-8.
9. Ogane N, Yasuda M, Shimizu M, et al. Clinicopathological implications of expressions of hypoxia-related molecules in esophageal superficial squamous cell carcinoma. Ann Diagn Pathol. 2010; 14: 23-9.
10. Sun HC, Qiu ZJ, Liu J, et al. Expression of hypoxia-inducible factor-1 alpha and associated proteins in pancreatic ductal adenocarcinoma and their impact on prognosis. Int J Oncol. 2007; 30: 1359-67.
11. Qiu MZ, Han B, Luo HY, et al. Expressions of hypoxia-inducible factor-1alpha and hexokinase-II in gastric adenocarcinoma: the impact on prognosis and correlation to clinicopathologic features. Tumour Biol. 2011; 32: 159-66.
12. Urano N, Fujiwara Y, Doki Y, et al. Overexpression of hypoxia-inducible factor-1 alpha in gastric adenocarcinoma. Gastric Cancer. 2006; 9: 44-9.
13. Griffiths EA, Pritchard SA, Valentine HR, et al. Hypoxia-inducible factor-1alpha expression in the gastric carcinogenesis sequence and its prognostic role in gastric and gastro-oesophageal adenocarcinomas. Br J Cancer. 2007; 96: 95-103.
14. Kawamura T, Kusakabe T, Sugino T, et al. Expression of glucose transporter-1 in human gastric carcinoma: association with tumor aggressiveness, metastasis, and patient survival. Cancer. 2001; 92: 634-41.
15. Li LG, Xu HM. Inducible nitric oxide synthase, nitrotyrosine and apoptosis in gastric adenocarcinomas and their correlation with a poor survival. World J Gastroenterol. 2005; 11: 2539-44.
16. Driessen A, Landuyt W, Pastorekova S, et al. Expression of carbonic anhydrase IX (CA IX), a hypoxia-related protein, rather than vascular-endothelial growth factor (VEGF), a pro-angiogenic factor, correlates with an extremely poor prognosis in esophageal and gastric adenocarcinomas. Ann Surg. 2006; 243: 334-40.
17. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003; 3: 721-32.
18. Luo XM, Zhou SH, Fan J. Glucose transporter-1 as a new therapeutic target in laryngeal carcinoma. J Int Med Res. 2010; 38: 1885-92.
19. Chen W, Foran DJ. Advances in cancer tissue microarray technology: Towards improved understanding and diagnostics. Anal Chim Acta. 2006; 564: 74-81.
20. Boone J, van Hillegersberg R, van Diest PJ, Offerhaus GJ, Rinkes IH, Kate FJ. Validation of tissue microarray technology in squamous cell carcinoma of the esophagus. Virchows Arch. 2008; 452: 507-14.
21. Mizokami K, Kakeji Y, Oda S, et al. Clinicopathologic significance of hypoxia-inducible factor 1alpha overexpression in gastric carcinomas. J Surg Oncol. 2006; 94: 149-54.
22. Zhang W, He XJ, Ma YY, et al. Inducible nitric oxide synthase expression correlates with angiogenesis, lymphangiogenesis, and poor prognosis in gastric cancer patients. Hum Pathol. 2011; 42: 1275-82.
23. Younes M, Juarez D, Lechago LV, Lerner SP. Glut 1 expression in transitional cell carcinoma of the urinary bladder is associated with poor patient survival. Anticancer Res. 2001; 21: 575-8.
24. Kunkel M, Reichert TE, Benz P, et al. Overexpression of Glut-1 and increased glucose metabolism in tumors are associated with a poor prognosis in patients with oral squamous cell carcinoma. Cancer. 2003; 97: 1015-24.
25. Noguchi Y, Marat D, Saito A, et al. Expression of facilitative glucose transporters in gastric tumors. Hepatogastroenterology. 1999; 46: 2683-9.